DOI QR코드

DOI QR Code

CYP2C19 Genotype Could be a Predictive Factor for Aggressive Manifestations of Hepatocellular Carcinoma Related with Chronic Hepatitis B Infection in Thailand

  • Nun-anan, Pongjarat (Gastroenterology Unit, Department of Medicine, Faculty of Medicine, Thammasat University Hospital, Pathumthani, and National Gastric Cancer and Helicobacter pylori Research Center) ;
  • Chonprasertsuk, Soonthorn (Gastroenterology Unit, Department of Medicine, Faculty of Medicine, Thammasat University Hospital, Pathumthani, and National Gastric Cancer and Helicobacter pylori Research Center) ;
  • Siramolpiwat, Sith (Gastroenterology Unit, Department of Medicine, Faculty of Medicine, Thammasat University Hospital, Pathumthani, and National Gastric Cancer and Helicobacter pylori Research Center) ;
  • Tangaroonsanti, Anupong (Gastroenterology Unit, Department of Medicine, Faculty of Medicine, Thammasat University Hospital, Pathumthani, and National Gastric Cancer and Helicobacter pylori Research Center) ;
  • Bhanthumkomol, Patommatat (Gastroenterology Unit, Department of Medicine, Faculty of Medicine, Thammasat University Hospital, Pathumthani, and National Gastric Cancer and Helicobacter pylori Research Center) ;
  • Pornthisarn, Bubpha (Gastroenterology Unit, Department of Medicine, Faculty of Medicine, Thammasat University Hospital, Pathumthani, and National Gastric Cancer and Helicobacter pylori Research Center) ;
  • Vilaichone, Ratha-korn (Gastroenterology Unit, Department of Medicine, Faculty of Medicine, Thammasat University Hospital, Pathumthani, and National Gastric Cancer and Helicobacter pylori Research Center)
  • Published : 2015.04.29

Abstract

Background: Chronic hepatitis B virus (HBV) infection related hepatocellular carcinoma (HCC) is a major health problem in the Asia-Pacific region including Thailand. Several factors have been proposed as contributing to hepatocarcinogenesis. This study was aimed to investigate the impact of CYP2C19 genotypic polymorphism in HCC related to chronic HBV infection in Thailand. Materials and Methods: A cross-sectional study was performed between April 2014 and January 2015. Chronic HBV patients with HCC (n=50) and without HCC (n=50) were included. Clinical information and blood samples of all patients were collected. The CYP2C19 genotype was determined by polymerase chain reaction-restriction fragment length polymorphism method, and was classified as rapid metabolizer (RM), intermediate metabolizer (IM) or poor metabolizer (PM). Results: The CYP2C19 genotype frequencies of RM, IM and PM in HBV patients were found to be 19/50 (38%), 25/50 (50%) and 6/50 (12%), respectively. The CYP2C19 genotype frequencies of RM, IM and PM in HBV with HCC patients were 21/50 (42%), 25/50 (50%) and 4/50 (8%), respectively. The distribution of CYP2C19 genotype was not different between patients with and without HCC. Interestingly, among HBV with HCC patients, the RM genotype of CYP2C19 tended to increase risk of aggressive manifestation (OR=2.89, 95%CI=0.76-11.25, P-value=0.07), compared with non RM genotype carriers. Conclusions: CYP2C19 genotype IM was the most common genotype in Thai patients with chronic HBV infection. In addition, genotype RM could be an associated factor for aggressive presentation in HCC related to chronic HBV infection.

Keywords

Hepatocellular carcinoma;hepatitis B virus;CYP2C19 genotype

Acknowledgement

Supported by : Faculty of Medicine, Thammasat University Hospital

References

  1. Abdelaziz AO, Elbaz TM, Shousha HI, et al (2014). Survival and prognostic factors for hepatocellular carcinoma: an egyptian multidisciplinary clinic experience. Asian Pac J Cancer Prev, 15, 3915-20. https://doi.org/10.7314/APJCP.2014.15.9.3915
  2. Bartosch B, Thimme R, Blum HE, Zoulim F (2009). Hepatitis C virus-induced hepatocarcinogenesis. J Hepatol, 51, 810-20. https://doi.org/10.1016/j.jhep.2009.05.008
  3. Brechot C (2004). Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms. Gastroenterol, 127, 56-61. https://doi.org/10.1053/j.gastro.2004.09.016
  4. Bruix J, Sherman M (2011). Management of hepatocellular carcinoma: an update. Hepatology, 53, 1020-2. https://doi.org/10.1002/hep.24199
  5. Chau TK, Marakami S, Kawai B, et al (2000). Genotype analysis of the CYP2C19 gene in HCV-seropositive patients with cirrhosis and hepatocellular carcinoma. Life Sci, 67, 1719-24. https://doi.org/10.1016/S0024-3205(00)00757-8
  6. Colombo M (1992). Hepatocellular carcinoma. J Hepatol, 15, 225-236. https://doi.org/10.1016/0168-8278(92)90041-M
  7. De Bac C, Stroffolini T, Gaeta GB, Taliani G, Giusti G. (1994). Pathogenic factors in cirrhosis with and without hepatocellular carcinoma: a multicenter Italian study. Hepatol, 20, 1225-30. https://doi.org/10.1002/hep.1840200519
  8. De Morais SM, Wilkinson GR, Blaisdell J, et al (1994). Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol, 46, 594-8.
  9. Fan JH, Wang JB, Jiang Y, et al (2013). Attributable causes of liver cancer mortality and incidence in china. Asian Pac J Cancer Prev, 14, 7251-6. https://doi.org/10.7314/APJCP.2013.14.12.7251
  10. Fujita K, Kamataki T (2001). Role of human cytochrome P450 (CYP) in the metabolic activation of N-alkylnitrosamines:application of genetically engineered Salmonella typhimurium YG7108 expressing each form of CYP together with human NADPH-cytochrome P450 reductase. Mutat Res, 483, 35-41. https://doi.org/10.1016/S0027-5107(01)00223-8
  11. Gearhart TL, Bouchard MJ (2010). The hepatitis B virus X protein modulates hepatocyte proliferation pathways to stimulate viral replication. J Virol, 84, 2675-86. https://doi.org/10.1128/JVI.02196-09
  12. Jainan W, Vilaichone RK (2014). Effects of the CYP2C19 genetic polymorphism on gastritis, peptic ulcer disease, peptic ulcer bleeding and gastric cancer. Asian Pac J Cancer Prev, 15, 10957-60.
  13. Kappers WA, Edwards RJ, Murray S, Boobis AR (2001). Diazinon is activated by CYP2C19 in human liver. Toxicol Appl Pharmacol, 177, 68-76. https://doi.org/10.1006/taap.2001.9294
  14. Khan G, Hashim MJ (2015). Burden of virus-associated liver cancer in the Arab world, 1990-2010. Asian Pac J Cancer Prev, 16, 265-70. https://doi.org/10.7314/APJCP.2015.16.1.265
  15. Liang T, Chen EQ, Tang H (2013). Hepatitis B virus gene mutations and hepatocarcinogenesis. Asian Pac J Cancer Prev, 14, 4509-13. https://doi.org/10.7314/APJCP.2013.14.8.4509
  16. McLaughlin-Drubin ME, K Munger (2008). Viruses associated with human cancer. Biochim Biophys Acta, 1782, 127-50. https://doi.org/10.1016/j.bbadis.2007.12.005
  17. Munaf A, Memon MS, Kumar P, Ahmed S, Kumar MB (2014). Comparison of viral hepatitis-associated hepatocellular carcinoma due to HBV and HCV - cohort from liver clinics in Pakistan. Asian Pac J Cancer Prev, 15, 7563-7. https://doi.org/10.7314/APJCP.2014.15.18.7563
  18. Murray CJ, Lopez AD (1997). Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet, 349, 1269-76. https://doi.org/10.1016/S0140-6736(96)07493-4
  19. Norsa'adah B, Nurhazalini-Zayani CG (2013). Epidemiology and survival of hepatocellular carcinoma in north-east Peninsular Malaysia. Asian Pac J Cancer Prev, 14, 6955-9. https://doi.org/10.7314/APJCP.2013.14.11.6955
  20. Okuda K (1992). Hepatocellular carcinoma: recent progress. Hepatol, 15, 948-63. https://doi.org/10.1002/hep.1840150532
  21. Sangmala P, Chaikledkaew U, Tanwandee T, Pongchareonsuk P (2014). Economic evaluation and budget impact analysis of the surveillance program for hepatocellular carcinoma in Thai chronic hepatitis B patients. Asian Pac J Cancer Prev, 15, 8993-9004. https://doi.org/10.7314/APJCP.2014.15.20.8993
  22. Shi WX, Chen SQ (2004). Frequencies of poor metabolizers of cytochrome P450 2C19 in esophagus cancer, stomach cancer, lung cancer and bladder cancer in Chinese population. World J Gastroenterol, 10, 1961-3. https://doi.org/10.3748/wjg.v10.i13.463
  23. Somboon K, Siramolpiwat S, Vilaichone RK (2014). Epidemiology and survival of hepatocellular carcinoma in the central region of Thailand. Asian Pac J Cancer Prev, 15, 3567-3570. https://doi.org/10.7314/APJCP.2014.15.8.3567
  24. Srinarong C, Siramolpiwat S, Wongcha-Um A, Mahachai V, Vilaichone RK (2014). Improved eradication rate of standard triple therapy by adding bismuth and probiotic supplement for Helicobacter pylori treatment in Thailand. Asian Pac J Cancer Prev, 15, 9909-13 https://doi.org/10.7314/APJCP.2014.15.22.9909
  25. Sugimoto M, Furuta T, Shirai N, et al (2004). Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status. Clin Pharmacol Ther, 76, 290-301. https://doi.org/10.1016/j.clpt.2004.06.008
  26. Tsuneoka Y, Fukushima K, Matsuo Y, Ichikawa Y, Watanabe Y (1996). Genotype analysis of the CYP2C19 gene in the Japanese population. Life Sci, 59, 1711-5. https://doi.org/10.1016/S0024-3205(96)00507-3
  27. Yamazaki Y, Fujita K, Nakayama K, et al (2004). Establishment of ten strains of genetically engineered Salmonella typhimurium TA1538 each co-expressing a form of human cytochrome P450 with NADPH-cytochrome P450 reductase sensitive to various promutagens. Mutat Res, 562, 151-62. https://doi.org/10.1016/j.mrgentox.2004.06.003
  28. Yeo Y, Gwack J, Kang S, et al (2013). Viral hepatitis and liver cancer in Korea: an epidemiological perspective. Asian Pac J Cancer Prev, 14, 6227-31. https://doi.org/10.7314/APJCP.2013.14.11.6227
  29. Zhou B, Song Z, Qian M, et al (2013). Functional polymorphisms in the CYP2C19 gene contribute to digestive system cancer risk: evidence from 11,042 subjects. PLoS One, 8, 66865. https://doi.org/10.1371/journal.pone.0066865